Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Aug;4(4):e1368.
doi: 10.1002/cnr2.1368. Epub 2021 Mar 31.

Statins and immunotherapy: Togetherness makes strength The potential effect of statins on immunotherapy for NSCLC

Alessandro Rossi  1 , Marco Filetti  1 , Beatrice Taurelli Salimbeni  1 , Marta Piras  1 , Francesco Rizzo  1 , Raffaele Giusti  1 , Paolo Marchetti  1
Affiliations
Observational Study

Statins and immunotherapy: Togetherness makes strength The potential effect of statins on immunotherapy for NSCLC

Alessandro Rossi et al. Cancer Rep (Hoboken). 2021 Aug.

Abstract

Background: Recent researches suggested that statins, beside their role in inhibiting endogenous cholesterol synthesis and in cardiovascular prevention, could influence several processes in cancer biology. In fact, a recent meta-analysis demonstrated that statins could positively influence OS in lung cancer patients.

Aim: There is a lack of large cohort studies that could support a potential antineoplastic role of statins in clinical practice. We collected data from 162 patients treated with immunotherapy for Nonsmall Cell Lung Cancer (NSCLC) in first- and second-line setting to investigate the impact of these drugs on survival parameters.

Methods and results: In our observational study, we enrolled 162 patients who received immunotherapy for lung cancer between October 2015 and April 2020. We used descriptive statistics to analyze patients' baseline features. Tumor response was evaluated using RECIST version 1.1 guidelines. Uni and multivariate analysis were conducted to investigate the relationship between statin use and response to immunotherapy, using the χ2 -test. We used Kaplan-Meier curves to estimate OS and PFS in statin and nonstatin users. We included 122 patients in the final analysis. Median PFS was 17.57 months in the statin group and 9.57 months in the nonstatin group, with a P = <.001. Moreover, median OS was superior in the statin-users group, with a statistically significant difference (19.94 vs 10.94 months, P = <.001).

Conclusion: Although in our study, statin use positively correlates with PFS and OS in lung cancer patient treated with immunotherapy, these results require a further validation with randomized clinical trials.

Keywords: NSCLC; immunotherapy; lung cancer; statins; survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

FIGURE 1
FIGURE 1
Kaplan–Meier curves that show overall survival of statin (red) and nonstatin (green) patients. P‐value between the two groups was <.001
FIGURE 2
FIGURE 2
Kaplan–Meier curves that show progression‐free survival of statin (red) and nonstatin (green) patients. P‐value between the two groups was <.001
See this image and copyright information in PMC

References

    1. Kubatka P, Kruzliak P, Rotrekl V, Jelinkova S, Mladosievicova B. Statins in oncological research: from experimental studies to clinical practice. Crit Rev Oncol Hematol. 2014;92(3):296‐311. - PubMed
    1. Sopková J, Vidomanová E, Strnádel J, Škovierová H, Halašová E. The role of statins as therapeutic agents in cancer. Gen Physiol Biophys. 2017;36(5):501‐511. - PubMed
    1. Farooqi MAM, Malhotra N, Mukherjee SD, et al. Statin therapy in the treatment of active cancer: a systematic review and meta‐analysis of randomized controlled trials. PLoS One. 2018;13(12):e0209486. - PMC - PubMed
    1. Fatehi Hassanabad A. Current perspectives on statins as potential anti‐cancer therapeutics: clinical outcomes and underlying molecular mechanisms. Transl Lung Cancer Res. 2019;8(5):692‐699. - PMC - PubMed
    1. De Groot PM, Wu CC, Carter BW, et al. The epidemiology of lung cancer. Transl Lung Cancer Res. 2018;7(3):220‐233. - PMC - PubMed

Publication types

MeSH terms

Substances